• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Small Pharma Inc (OP: DMTTF )

    N/A UNCHANGED
    Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Small Pharma Inc

    < Previous 1 2 3 4 5 6 7 Next >
    Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
    A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub 
    Via Benzinga
    Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
    Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
    Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
    Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. 
    Via Benzinga
    Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
    Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts 
    Via Benzinga
    Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
    Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. 
    Via Benzinga
    Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement
    Short-acting psychedelics biotech Small Pharma Inc. 
    Via Benzinga
    Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
    Cybin And Small Pharma Shareholders Green Light Acquisition Resolution 
    Via Benzinga
    Exposures Product Safety
    Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
    Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. 
    Via Benzinga
    Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
    Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
    Via Benzinga
    Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
    New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. 
    Via Benzinga
    Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
    Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
    Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... 
    Via Benzinga
    Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
    Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). 
    Via Benzinga
    Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT
    The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and... 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
    Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
    Via Benzinga
    Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
    Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... 
    Via Benzinga
    Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M
    Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9... 
    Via Benzinga
    Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
    Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o 
    Via Benzinga
    Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
    A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
    Via Benzinga
    Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
    UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
    Via Benzinga
    Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
    First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
    Via Benzinga
    Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change
    Together with reporting its annual financial results and pipeline update, short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) stated its intentions to 
    Via Benzinga
    Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
    World's Largest Psychedelics Conference Boasts 12K Attendees 
    Via Benzinga
    Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses
    UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates.  Highlights: 
    Via Benzinga
    Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
    Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
    Via Benzinga
    Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World
    U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe. 
    Via Benzinga
    DMT For Major Depression Shows Remarkable Benefits After Six-Month Trial
    Short-acting psychedelics company Small Pharma Inc. 
    Via Benzinga
    EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
    This is the third article of a three-part series, you can find the first and 
    Via Benzinga
    Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
    Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.